Pulmocide Grows Cash Pile For Promising Antifungal
Opelconazole In Phase III For Invasive Pulmonary Aspergillosis
The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.
